Due to ErbB2 and ErbB3 mutations at a frequency of 7–8% in GBC, ErbB2/ErbB3 mutation inducing PD-L1 overexpression can mediate immune escape of tumor cells via PI3K/AKT pathway in vitro [148]. Here, PIK3CB is linked to neoplasm.